Prostate cancer
Conditions
Interventions
Experimental group:Traditional Chinese Medicine+Novel endocrine therapy
Control group:Novel endocrine therapy
Sponsors
Guangdong Hospital of Traditional Chinese Medicine
Eligibility
Sex/Gender
Male
Age
40 Years to 85 Years
Inclusion criteria
Inclusion criteria: Pathological diagnosis of prostate adenocarcinoma; The patient was diagnosed with bone metastasis by bone ECT, CT, MRI, PET/CT, etc. And/or the pathological diagnosis of bone is bone metastatic cancer of the prostate; Kanofsky score =60, life expectancy =6 months; Informed consent, and willing to cooperate with treatment, accept observation, compliance is good.
Exclusion criteria
Exclusion criteria: Poor compliance, incomplete data; Patients with severe heart, liver and kidney diseases; Targeted drug therapy; People with a history of mental illness. Are participating in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prostate specific antigen;Median progression time;PFS; | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum testosterone, bone metabolism markers (alkaline phosphatase ALP and bone metabolites: total type I collagen amino terminal elongation peptide ß Collagen special series, N-terminal intermediate molecular fragments of osteocalcin, blood calcium monitoring;Symptom improvement (Quantitative Standards for Traditional Chinese Medicine Symptoms);Improvement of prostate symptoms (IPSS);Quality of life ;Cancer pain (VAS);Local lesions;Bone metastasis and systemic condition;Monitoring of testosterone, immune cell, CTCs, and AR levels;OS, CSS;Median time of transition to castration; | — |
Countries
China
Contacts
Public ContactGu Chiming
Guangdong Hospital of Traditional Chinese Medicine
Outcome results
None listed